monoclonal antibodies

May 8, 2024

Supercomputing redesign of a COVID monoclonal antibody

The approach, which combines high-performance computing, simulation, machine learning and experimental validation, will help keep antibody drugs up to date in the future against highly variable viruses.

(courtesy of the CDC)
April 4, 2024

Tick bites and alpha-gal syndrome focus of $3.5M research grant

Vanderbilt’s Scott Smith, MD, PhD, has been awarded a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to study the human immune response to tick bites and its role in preventing tick-borne illnesses.

March 28, 2024

VUMC team discovers antibodies that may prevent severe respiratory illness

Using a technique developed at Vanderbilt University Medical Center, researchers identified antibodies that are excellent leads as potential therapies for human parainfluenza virus 3, a leading cause of acute and potentially fatal respiratory illness.

November 6, 2023

Children’s antibodies highly potent against COVID-19: study

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.

September 13, 2023

James Crowe’s antibody research lands American Society for Microbiology Award

Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.

James Crowe, Jr., MD, left, and Naveenchandra Suryadevara, PhD, have discovered a monoclonal antibody with therapeutic potential that neutralizes both RSV and hMPV. (photo by Anthony Czelusniak)
August 4, 2023

Researchers discover antibody that neutralizes both RSV and hMPV

Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.